Drug Trial Radar · NCT06290713
Vasodilator and Exercise Study for DMD (VASO-REx)
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 5, 2024
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- University of FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- First posted
- Mar 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.
Conditions
- Duchenne Muscular Dystrophy
- Duchenne Disease
- Muscular Dystrophy
- Muscular Dystrophy in Children
- Vasodilation
- Exercise
- DMD
Interventions
TadalafilDrug
Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
PlaceboDrug
Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
Exercise TrainingOther
The home-based cycling exercise training program is designed to improve muscle strength and endurance. Participants will engage in individualized exercise sessions up to four times per week, lasting up to 40 minutes each. Live video and heart rate monitoring will ensure proper exercise performance and allow for adjustments to the program throughout the study. The participants will receive the exercise equipment for use at home.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vascular responsiveness after muscle contraction to a single dose of tadalafil.Time frame: up to 4 weeks after the completion of Visits 1 and 2 of Aim 1.
- Cycling time to fatigueTime frame: Baseline and 6 month follow-up visits of Aim 2.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Florida Clinical and Translational Research Building
Gainesville, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.